Olema PharmaceuticalsOLMA
OLMA
About: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Employees: 102
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
15% less funds holding
Funds holding: 156 [Q4 2024] → 132 (-24) [Q1 2025]
27.97% less ownership
Funds ownership: 124.4% [Q4 2024] → 96.43% (-27.97%) [Q1 2025]
40% less capital invested
Capital invested by funds: $415M [Q4 2024] → $248M (-$167M) [Q1 2025]
49% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 47
79% less call options, than puts
Call options by funds: $27K | Put options by funds: $128K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
332%
upside
Avg. target
$25
488%
upside
High target
$30
619%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Richard Law | 332%upside $18 | Buy Maintained | 14 May 2025 |
Oppenheimer Matthew Biegler | 428%upside $22 | Outperform Maintained | 14 May 2025 |
HC Wainwright & Co. Emily Bodnar | 619%upside $30 | Buy Reiterated | 28 Apr 2025 |
JP Morgan Anupam Rama | 571%upside $28 | Overweight Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about OLMA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 weeks ago
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer. This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago, Illinois. The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.
Neutral
GlobeNewsWire
3 weeks ago
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 study Pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual Meeting Preclinical data for OP-3136 presented at AACR demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models; Phase 1 trial recruitment ongoing Ended the first quarter with $392.7 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May 13, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2025. “During the first quarter, we continued to make important operational progress advancing our pipeline and we enter the second quarter well-positioned across the business,” said Sean P.
Neutral
GlobeNewsWire
1 month ago
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer (NSCLC) models. These findings are being presented in a late-breaking poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Negative
Zacks Investment Research
2 months ago
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™